The Liver Disease Symptom Index 2.0; Validation of a Disease-Specific Questionnaire
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The available liver disease-specific questionnaires do address severity of symptoms but hardly evaluate how patients experience these specific symptoms during daily activities. The Liver Disease Symptom Index 2.0 (LDSI) includes 18 items that measure symptom severity and symptom hindrance in the past week. In a large survey (n = 1175) conducted in collaboration with the Dutch liver patient association, convergent and divergent construct validity and the surplus value of including symptom severity and symptom hindrance items in the LDSI were examined. The LDSI items showed expected convergent and divergent correlations with Short Form-36 (SF-36) and Multidimensional Fatigue Index-20 (MFI-20) scales. Correlations revealed only a slight to moderate overlap between LDSI items and SF-36 and MFI-20 scales. The impact of symptom severity and symptom hindrance on generic health related quality of life (HRQoL) varied in a different way across liver patients, which indicated that symptom severity items and the symptom hindrance items measure different aspects of HRQoL. We conclude that the LDSI provides information complementary to the information given by the SF-36 and the MFI-20 and that it is psychometrically sound to include both symptom severity items and symptom hindrance items in the LDSI.
- Younossi ZM. Chronic liver disease and health-related quality of life. Gastroenterology 2001;120:305–307.
- Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a signi cant reduction in quality of life in the absence of cirrhosis. Hepatology 1998;27:209–212.
- Davis GL, Balart LA, Schiff ER, et al. Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile. Clin Ther 1994;16:334–343 (discussion 271–332).
- Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 1999;29:264–270.
- Bianchi G, Loguercio C, Sgarbi D, et al. Reduced quality of life in patients with chronic hepatitis C: Effects of interferon treatment. Dig Liver Dis 2000;32:398–405.
- Bayliss MS, Gandek B, Bungay KM, Sugano D, Hsu MA, Ware JE, Jr. A questionnaire to assess the generic and disease-speci c health outcomes of patients with chronic hepatitis C. Qual Life Res 1998;7:39–55.
- Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D. Development of a disease speci c questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 1999;45:295–300.
- Gralnek IM, Hays RD, Kilbourne A, et al. Development and evaluation of the Liver Disease Quality of Life instrument in persons with advanced, chronic liver disease–the LDQOL 1. 0. Am J Gastroenterol 2000;95:3552–3565.
- Huet PM, Deslauriers J, Tran A, Faucher C, Charbonneau J. Impact of fatigue on the quality of life of patients with primary biliary cirrhosis. Am J Gastroenterol 2000;95: 760–767.
- Miller ER, Hiller JE, Shaw DR. Quality of life in HCV-infection:Lack of association with ALT levels. Aust N Z J Public Health 2001;25:355–361.
- Watson D, Pennebaker JW. Health complaints, stress, and distress:Exploring the central role of negative affectivity. Psychol Rev 1989;96:234–254.
- Unal G, de Boer JB, Borsboom GJ, Brouwer JT, Essink-Bot M, de Man RA. A psychometric comparison of health-related quality of life measures in chronic liver disease. J Clin Epidemiol 2001;54:587–596.
- Lauterburg BH, Pineda AA, Dickson ER, Baldus WP, Taswell HF. Plasmaperfusion for the treatment of intrac-table pruritus of cholestasis. Mayo Clin Proc 1978;53:403–407.
- Bergasa NV, Alling DW, Talbot TL, et al. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med 1995;123:161–167.
- Ware JE, Jr., Snow KK, Kosinski M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide. Boston: The health institute, New England Medical Center, 1994.
- Smets EMA, Garssen B, Bonke B: Het meten van ver-moeidheid met de multidimensionele vermoeidheidsindex (MVI-20), een handleiding. University of Amsterdam, Department of Medical Psychology, 1995.
- Aadahl M, Hansen BA, Kirkegaard P, Groenvold M. Fatigue and physical function after orthotopic liver transplantation. Liver Transpl 2002;8:251–259.
- Goldblatt J, Taylor PJ, Lipman T, et al. The true impact of fatigue in primary biliary cirrhosis:A population study. Gastroenterology 2002;122:1235–1241.
- Fayers PM, Machin D. Quality of Life, Assesment, Analysis and Interpretation. Chichester: John Wiley & Sons, Ltd, 2000.
- Simon GE: Treating depression in patients with chronic disease:Recognition and treatment are crucial;depression worsens the course of a chronic illness. West J Med 2001; 175:292–293.
- The Liver Disease Symptom Index 2.0; Validation of a Disease-Specific Questionnaire
Quality of Life Research
Volume 13, Issue 8 , pp 1469-1481
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers
- Additional Links
- Liver diseases
- Quality of life
- Validity (epidemiology)
- Industry Sectors
- Author Affiliations
- 1. Department of Gastroenterology and Hepatology, Erasmus Medical Center Rotterdam, The Netherlands
- 2. Department of Medical Psychology and Psychotherapy, Erasmus Medical Center Rotterdam, The Netherlands
- 3. Department of Epidemiology and Biostatistics, Erasmus Medical Center Rotterdam, The Netherlands